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Abstract
Background: Increasing evidence suggests an unexpected potential for non-neutralizing antibodies to prevent
HIV infection. Consequently, identification of functional linear B-cell epitopes for HIV are important for developing
preventative and therapeutic strategies. We therefore explored the role of antigen-specific immune responses in
controlling plasma viremia in SIV infected rhesus macaques.
Methods: Thirteen rhesus macaques were inoculated either intravaginally or intrarectally with SIVMAC251. Peripheral blood
CD4+ T-cells were quantified. Plasma was examined for viremia, antigen specific IgG, IgA and IgM binding responses
and neutralizing antibodies. Regions containing binding epitopes for antigen-specific IgG, IgM and IgA responses were
determined, and the minimum size of linear Envelope epitope responsible for binding antibodies was identified.
Results: The presence of neutralizing antibodies did not correlate the outcome of the disease. In a few SIV-infected
macaques, antigen-specific IgG and IgM responses in plasma correlated with decreased plasma viremia. Early induction
and the breadth of antigen-specific IgG responses were found to be significantly correlated with the control of plasma
viral load. Immunoglobulin classes share similar functional linear B-cell epitopes. SIV-specific linear envelope B-cell epitopes
were found to be 12 amino-acids in length.
Conclusions: Early induction of combination of peptide-specific IgG responses were found to be responsible for the
control of plasma viral load and indicative of disease outcome in SIV-infected rhesus macaques and might be important
for the development of therapeutic strategies for control or prevention of HIV/AIDS.
Keywords: Antibody, Breadth, Correlate of protection, Neutralizing antibodies, Peptides, Rhesus macaque, SIV, SIV-antigens
Background
HIV-1 infection is associated with polyclonal B-cell activa-
tion, hypergammaglobulinemia, the presence of immature/
transitional CD10+ or exhausted CD27 negative B-cells in
blood [1, 2], exhaustion of tissue-like memory (CD20(hi)/
CD27(−)/CD21(lo)) B-cells [3], loss of total B-cell popula-
tions [4, 5], and nonspecific switching from IgM to IgG,
IgA and IgE responses. Our recent data demonstrated
defective memory (CD21 + CD27+) B-cell proliferation in
selective tissues in simian immunodeficiency virus (SIV)-
infected macaques [6, 7]. Therefore, the maintenance of
normal and effective humoral immune responses may be
the key to the prevention and control of HIV/SIV infec-
tion. Recent reports emphasize that HIV-specific anti-
bodies (Abs), instead of T-cell responses, may correlate
better with protection in seronegative partners of HIV-1
infected individuals [8]. Moreover, other emerging studies
demonstrate a correlation between anti-HIV antibodies
and protection from infection, although these protective
Abs are not strictly neutralizing in vitro [9]. Furthermore,
lymphocytic choriomeningitis virus infection in the mouse
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model has also shown that non-neutralizing Abs elicited
early in infection are capable of binding to the virus and
limiting it's spread [10].
B-cell epitopes are described either as conformational
(discontinuous, assembled) epitopes where multiple dis-
continuous amino-acids (aa) segments are folded to pro-
duce a unique conformational epitope complementary
to the antibody, termed a contact epitope [11–14], or
linear epitopes (continuous, sequential) where epitopes
do not incorporate protein folding and can be repre-
sented by linear peptide sequence [15]. The continuous
maturation of the immune response following SIV infec-
tion emphasizes the need to study the generation of
SIV-specific Ab responses, antigen-antibody binding effi-
cacy, and their potential importance in regulating disease
progression.
The present study was designed to determine the
importance of total immunoglobulin, antigen-specific
immunoglobulin responses against whole viral lysate
(WVL), peptides corresponding to Env, Gag, Nef, and
Tat and neutralizing antibodies (NAbs) in controlling
plasma viral load (pVL) in SIVMAC251 infected rhesus
macaques (RMs). Regions containing binding epitopes
for antigen-specific IgG, IgM and IgA responses during
different stages of SIV infection were determined, and
the minimum size of linear Env epitope responsible for
binding Abs was identified. Our findings suggest that
conformational IgG and IgM responses as well as
breadth of different peptide-specific functional IgG re-
sponses are indicative of disease outcome. The presence
of NAbs against neutralization-sensitive and resistant
pseudovirus did not predict the outcome of the disease.
Methods
Animals
All animals in this study were housed at the Tulane
National Primate Research Center (TNPRC) in accord-
ance with the standards incorporated in the Guide for
the Care and Use of Laboratory Animals [16]. All of
TNPRC animal housing meets the Laboratory and
Animal Biosafety Level 2+ requirements recommended
for hepatitis, AIDS, and other viral agents related studies
in the CDC/NIH publication “Biosafety in Microbiological
and Biomedical Laboratories”. The Tulane Institutional
Animal Care and Use Committee (IACUC) of the TNPRC
approved all animal procedures related to this manuscript.
The TNPRC is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care
(Animal Welfare Assurance A-4499-01). Virus inocula-
tion, sample collections from animals were performed
under the direction of veterinarians. Every effort was
made to avoid unnecessary discomfort and pain to ani-
mals. At the TNPRC, animal discomfort or pain was al-
leviated by appropriate use of anesthetic medications.
Rhesus macaques were sedated with ketamine (10 mg/
kg body weight) whenever they were removed from
their home cage for routine blood collection, physical
examinations or other minor procedures. Animals were
euthanized humanely using the standard method of eu-
thanasia for nonhuman primates, where animals were
euthanized using Telazol and buprenorphine followed by
a lethal intravenous dose of sodium pentobarbital. This
method was consistent with the recommendation of the
American Veterinary Medical Association Guidelines.
Animal and tissue sampling
Thirteen adult Indian RMs (Macaca mulatta), initially
negative for SIV, HIV-2, type D retrovirus and simian
T-cell leukemia virus 1 infection were inoculated with
300–500 TCID50 of SIVMAC251-CX intravaginally
(Ivag) or intrarectally (IR) (Table 1). Two out of 13
RMs were positive for Mamu-A*01 and majority were
negative for Mamu-B*17 alleles. Mamu-A*01 and
Mamu-B*17 alleles were found to be linked with
lower viral set points and slow disease progression in
SIV infected RMs [17–20]. However, the independent
presence of Mamu-B*17 allele does not predict the
outcome of SIV infection [21]. Intravaginally inocu-
lated female macaques were treated with depot
medroxyprogesterone acetate (30 mg intramuscularly)
28d prior to SIV exposure [22]. Sodium heparin and
EDTA peripheral blood (PB) were collected at se-
quential time points for analysis described below.
Plasma viral load quantification
Plasma viral RNA was quantified either by bDNA sig-
nal amplification assay for IR macaques (Siemens
Diagnostics, USA) [22, 23] or by quantitative RT-PCR
assay for Ivag macaques (Wisconsin National Primate
Research Center Virology Core laboratory) [24, 25].
The lower limit of RNA detection for bDNA and RT-
PCR assays were 125 and 60 SIV-RNA copies/ml of
plasma respectively.
Peripheral blood T-cell immunophenotyping
PB T-cell immunophenotyping was performed using
anti-CD3-FITC (SP34-2), anti-CD4-APC (L200) and
anti-CD8-PE (RPA-T8) monoclonal antibodies (MAbs)
obtained from BD Biosciences as reported earlier [5, 26].
At least 20,000 events were collected by gating on
lymphocytes. Data were acquired in a BD LSRII flow cyt-
ometer within 24 h after staining and analyzed further
using FlowJo software (TreeStar Inc.) [5, 27]. Absolute
count of CD4+ T-cell population was calculated using
flow cytometry and CBC data.
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Neutralization assay
Neutralizing antibody (NAb) activity was measured
in 96-well culture plates by using Tat-regulated lucif-
erase (Luc) reporter gene expression to quantify
reductions in virus infection in TZM-bl cells against
the neutralization-sensitive SIVMAC251.6 and the
neutralization-resistant SIVMAC251.30 pseudoviruses,
using MLV-pseudotyped virus as a negative control
for non-specific virus inhibition as described previ-
ously [28]. TZM-bl cells were obtained from the
NIH AIDS Research and Reference Reagent Program,
as contributed by John Kappes and Xiaoyun Wu.
Heat inactivated plasma samples were diluted over a
range of 1:20 to 1:43740 in cell culture medium and
pre-incubated with virus (~150,000 relative light unit
equivalents) for 1 h at 37 ºC before addition of cells.
Following a 48 h incubation, cells were lysed and
Luc activity determined using a microtiter plate
luminometer and BriteLite Plus Reagent (Perkin
Elmer). Neutralization titers are the sample dilution
at which relative luminescence units (RLU) were re-
duced by 50% compared to RLU in virus control
wells after subtraction of background RLU in cell
control wells.
Measurement of antigen-specific and total immunoglobulin
responses
Antigen-specific IgG, IgA and IgM were detected in
plasma using ELISA as previously described [5, 29, 30].
Purified SIVMAC251 WVL was used as coating antigen
(5 μg/ml, Applied Biosystems) to quantify antibody re-
sponses against conformational/discontinuous epitopes.
Total IgG, IgM and IgA concentrations were measured
by ELISA as previously described [5, 7], where plates
were coated with either anti-monkey IgG Fc/7s (Accur-
ate Chemicals), IgM Fc (Accurate Chemicals) or IgA Fc
(Alpha Diagnostic International) Abs. All samples were
assayed in duplicate with appropriate positive and negative
controls. For quantification of WVL-specific and total im-
munoglobulin responses, rhesus IgG, IgA (NIH-Nonhu-
man Primate Reagent Resource) and IgM (Fitzgerald
Industries International) standards were used. Nonlinear
regression using a sigmoidal dose-response variable slope
model was used to interpolate concentrations from the
standard curve. For WVL-specific Ig responses, positive
values had to exceed the mean + 2SD of all animal’s pre-
infection readings for a specific antigen at absorbance
490 nm. To increase stringency and to account for vari-
ation between animals, the absorbance values for each













Progressor Major Pathological Findings
Intravaginal (Ivag) BC35 12.0 F 300 - ND - -
CL86 10.4 F 500 - ND + Severe lymphoid hyperplasia and dysplasia in
spleen, all lymph nodes, tonsil, and many other
organs; Mild intestinal pneumonia
CL87 10.0 F 300 - ND - -
DE50 9.4 F 500 - - + Generalized amyloidosis and lymphoid hyperplasia
FK88 5.9 F 500 - - + Mild to moderate lymphoid hyperplasia and
dysplasia in spleen, multiple lymph nodes and
organs
GN91 3.8 F 500 - - - -
Intrarectal (IR) AE14 8.0 M 500 - - + Amyloid deposits in the liver; small number of
pneumocystis and SIV giant cells in lung;
Cryptosporidium infection in small intestine
AP09 7.3 M 500 + - - -
AP64 7.0 M 500 - - - -
BG21 6.3 M 500 - - - -
N107 12.4 M 500 - - - -
P205 11.4 F 500 - - + Amyloidosis in the small intestine and enterocolitis;
lesions in lung are typical of viral pneumonia with
presence of SIV giant cells
T153 9.5 F 500 + - - -
aF and M denote female and male respectively; bTCID50: Tissue culture infectivity dose at 50%; ND: not done; “+” and “-“ denotes positive and negative results
respectively for the respective column
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individual animal also had to exceed two times the value
for the specific animal prior to infection to be classified as
positive.
Measurement of peptide-specific immunoglobulin
responses
SIV-Env (catalog- 6883), SIV-Gag (catalog- 6204), SIV-
Nef (catalog- 8762), and SIV-Tat (catalog- 6207) 15-mers
with 11-aa overlap peptides (NIH AIDS Research and
Reference Reagent Program) were used as coating anti-
gen. Plates were coated with peptide pools (PPs, 4–10
peptides per pool, 5 μg/ml of each peptide in 0.1 M so-
dium carbonate monohydrate, pH 9.6) to determine
antibody responses generated against linear/continuous
epitopes by ELISA as described earlier [5, 29, 30]. For all
peptide-specific ELISA values, the positive responses
were determined as specified above for WVL-specific re-
sponses. Cumulative OD values were calculated by the
summation of OD/490 values for each positive peptide
pool, after subtraction of the pre-infection value for each
peptide pool in a protein.
Statistical analysis
Statistical significance for immunoglobulin quantitation
data was determined using a one-way ANOVA. The
Bonferroni method was used as a post hoc multiple com-
parison test for all means. Statistical differences between
groups were tested using a two-tailed unpaired t-test.
Pearson coefficient of determination analysis was per-
formed to calculate correlation between pVLs and im-
munoglobulin responses and between pVLs and breadth
of antigen-specific antibody responses using SAS soft-
ware (version 9 in a windows environment). For all ana-
lyses, P values <0.05 were considered significant.
Results
Plasma viral load and peripheral CD4+ count demonstrate
the progression of SIV infection in SIV-infected macaques
Male to female/female to male and male to male sexual
transmission via intravaginal and intrarectal route re-
spectively are responsible for 75–85% of the HIV trans-
mission [31]. In this study, we have used two groups of
animals inoculated via Ivag (represents male to female
transmission) or IR (represents male to male transmis-
sion) route to determine whether the inoculation route
had any effect in regulating antigen-specific antibody
and neutralizing antibody responses. We were also inter-
ested to determine whether the inoculation route had
any impact on the breadth of immune responses. In all
SIV-infected RMs, peak plasma viral replication (log10
6.3–7.8 RNA copies/ml of plasma) was detected between
14 and 21 day post infection (dpi, Fig. 1a). Only one ani-
mal GN91 was able to control pVL to approximately 1 ×
103 RNA copies/ml of plasma following the initial peak
of viremia (Fig. 1), whereas the remaining animals had
plasma SIV-RNA greater than 10,000 copies/ml of
plasma. Several of these animals (CL86, DE50, FK88,
AE14, and P205) progressed to AIDS rapidly and were
euthanized accordingly (Table 1). There were no differ-
ence in the mean viral set points (measured 25 to 95dpi)
between Ivag and IR infected RMs.
Following SIVMAC251 infection, absolute CD4 count
in peripheral blood decreased rapidly in the majority of
the animals except GN91, in which CD4+ T-cell count
decreased after 150dpi (Fig. 1a). Animal N107 had a low
peripheral CD4+ T-cell count from the beginning com-
pared to other macaques and by 18dpi the CD4+ T-cell
count was below 200 cells/μl of blood and remained low
throughout this study. The absolute CD4+ T-cell counts
do not completely reflect the status of pVL as AE14 and
BG21 had similar patterns of CD4+ T-cell count in per-
ipheral blood, however the plasma viral load in AE14
remained 2.2 log higher than the viral load in BG21
from 68dpi onwards.
Neutralizing antibody titers did not predict the disease
outcome or the progression of disease
All thirteen RMs were selected to perform NAb assays
at several different time points after SIV infection
(Table 2). Neutralization of the highly neutralization-
sensitive Tier 1A virus, SIVmac251.6 was detectable in
all animals by 25–27 days post-infection and rose to very
high titers over the time course of the samples received.
Out of a total of 13 RMs, neutralization of SIV-
mac251.30, which exhibits an insensitive Tier 3
neutralization phenotype that more closely approximates
the infecting virus, was detected at 42 and/or 95dpi in 4
RMs and at 257dpi in 1 RM. A few of the titers were
fairly high in RMs AE14, AP09, CL87 and P205. How-
ever, AE14 and P205 progressed to AIDS rapidly despite
the presence of NAb titers against neutralization-
resistant SIVmac251.30 pseudovirus (Table 2). We did
not observe any difference in Nab titers between Ivag
and IR infected RMs.
In a few SIV-infected macaques, antigen–specific IgG and
IgM responses in plasma correlated with decreased
plasma viremia
Total and WVL-specific IgG, IgM and IgA responses
were measured in both IVag and IR inoculated SIV in-
fected macaques (Fig. 2 and Additional file 1: Table S1).
Total IgG concentration remained largely consistent
(IVag: 2989–9367 μg/ml; IR: 1533–4028 μg/ml) while
SIV-specific IgG responses increased significantly during
the course of SIV infection in both IVag and IR infected
macaques (geometric mean values 1084 μg/ml at
257 days post infection (dpi) and 334 μg/ml at 272dpi in
IVag and IR infection respectively; Fig. 2). Increased
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Fig. 1 (See legend on next page.)
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SIV-specific IgG responses in chronic infection corres-
pond with increased peptide-specific IgG responses in
both groups. Total IgM concentration also did not vary
significantly throughout the course of infection (IVag:
550–1777 μg/ml; IR: 1503–3393 μg/ml; Additional file 1:
Table S1). However, SIV infected macaques showed an
early peak in SIV-specific IgM concentrations in acute
infection (Ivag: geometric mean value 1.1 μg/ml at
27dpi; IR: mean value 0.7 μg/ml at 25dpi; Fig. 2) that de-
creased at later time points. SIV-specific IgM concentra-
tions were lower in animals infected via the IR route,
however, the trend between the two inoculation routes
remained same. Total IgA responses varied non-
significantly throughout infection (IVag: 632–1388 μg/
ml; IR: 797–1093 μg/ml; Additional file 1: Table S1).
However, SIV-specific IgA responses were detected in 5
out of 6 Ivag infected RMs and the level peaked at
73dpi. AE14 from IR infected RMs did not generate
WVL-specific IgA responses and the overall IgA titer in
rest of the IR infected animals was lower than Ivag in-
fected RMs (Fig. 2).
Pearson coefficient of determination analysis was
performed to determine correlation between pVLs and
immunoglobulin responses (20dpi to 257dpi and 25dpi
to 272dpi for Ivag and IR RMs respectively, Fig. 1b) as
reported earlier [32]. Total Ab responses in four (BC35,
DE50, AE14 and AP09) out of thirteen macaques were
negatively correlated with pVLs suggesting that total
IgG, IgM or IgA had minimal role in controlling pVL
(Fig. 1b). Similarly WVL-specific Ab responses in four
(BC35, CL87, GN91 and AP09) out of thirteen RMs
were negatively correlated with pVLs suggested that
WVL-specific IgG or IgM also had minimal role in con-
trolling pVL (Fig. 1b).
Combination of different peptide-specific IgG responses
found to correlate with the control of plasma viral load
Similar to WVL-specific immunoglobulin responses,
peptide-specific immunoglobulin responses measured by
cumulative OD values were also correlated with pVLs
for all RMs to determine if any of the peptide-specific
responses may represent a key predictor for the control
of plasma viremia. Cumulative IgG responses against
Env, Gag, Nef and Tat linear peptides show statistically
significant negative correlations in eight, four, three and
one RM respectively (Fig. 1b). RM GN91 maintained
pVL to approximately 103 RNA copies/ml, where Env,
Gag, Nef and Tat specific IgG responses significantly
upregulated, which might be playing a key role in con-
trolling pVL. Significant negative correlations between
Env-specific IgG responses and pVL in three disease
progressing RMs (CL86, DE50 and FK88, Table 1) sug-
gested that single antigen-specific responses were not
adequate to control pVL and/or the disease progression
and a combination of different peptide-specific IgG re-
sponses might be important in controlling pVL. Despite
several significant negative correlations detected be-
tween antigen-specific IgM and IgA responses and pVLs,
these independent responses did not predict the disease
outcome (Fig. 1b). The breadth of IgG responses (IgG
responses against antigens like Env, Gag, Nef and/or
Tat) were also correlated with pVLs in all animals
(Fig. 3). One (GN91) out of total 13 RMs had significant
negative correlation between pVL and the number of
antigen responses (r = −0.64, p-value = 0.035; Fig. 3b),
which suggested that breadth of antibody responses had
an impact in controlling pVL. Infact, three (Env, Gag
and Nef) antigen-specific IgG responses in GN91 were
detected as early as 55dpi and by 126dpi IgG responses
were prevalently detected against all four antigens (Env,
Gag, Nef and Tat) and remained high throughout the time
point of this study (Fig. 3a). No other animals had such
early and increased breadth of IgG responses detected in
this study. The breadth of IgG responses was evident more
in Ivag compared to IR infected RMs where all Ivag animals
had two or more antigen-specific IgG responses detected
(Fig. 3a). AE14 RM from IR group had shown no detectable
antigen-specific responses upto 236dpi. Another two RMs
(N107 and P205) from IR group had shown selective Env-
specific IgG responses throughout the study period. No sig-
nificant correlation was detected between breadth of IgM
or IgA responses and pVLs in any of these animals.
(See figure on previous page.)
Fig. 1 a Plasma viral load and absolute CD4+ T-lymphocyte counts over the course of 257 days for intravaginally (Ivag, n = 6, upper rows) and
272 days for intrarectally (IR, n = 7, bottom rows) SIVMAC251 inoculated macaques were shown. One macaques, GN91 was able to maintain plasma
viral load to approximately 1 × 103 RNA copies/ml of plasma following the initial peak of infection. The remaining macaques retained a high viral
load throughout infection amongst which CL86, DE50, FK88, AE14 and P205 progressed to AIDS rapidly and were euthanized accordingly. Note
GN91 was able to preserve peripheral CD4+ T-cell population after SIV infection for upto 150dpi. b Pearson coefficient of determination analysis
between plasma viral load and either total immunoglobulins or antigen specific immunoglobulins were shown for all macaques following SIVMAC251
inoculation for all time points. No significant correlation between plasma viral load and total or antigen-specific immunoglobulin responses were
detected in two macaques (AP64 and P205) for all time specified above. Additionally, no significant correlations were found for WVL-specific IgA or
peptide-specific IgM for Env and Nef. No Tat or Nef-specific IgA responses were detected. R and P denote Pearson R and probability values respectively
for each row when correlated with plasma viral load. NS denotes non-significant P-value (p > 0.05). ND denotes a correlation cannot be calculated.
Significant correlation values were shown in bold numbers
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Immunoglobulin classes share similar functional linear B-
cell epitopes
Individual 15-mer peptides (11-aa overlap) for SIV-Env,
Gag and Nef antigens were used to identify functional
linear B-cell epitopes using antigen specific ELISA
protocol mentioned above (Figs. 4 and 5). In general,
peptide-specific IgG responses were detected against
multiple regions of all proteins and increased following
SIV infection in both Ivag and IR inoculated macaques
(Figs. 4b and 5b, f ). By 73dpi all Ivag infected RMs
responded to both SIV-Gag and Env PPs with 100%
responding to Env PP16 and 19 and Gag PP11 (Figs. 4b
and 5b). Conversely, some macaques infected via the IR
route did not respond to any PPs until 272dpi, when
100% of animals responded to Env PP16 (Figs. 4b and
5b). Peptide-specific IgM responses in Ivag infected ma-
caques appeared during early infection and diminished
overtime (Figs. 4c and 5c, g, i). Peptide-specific IgA re-
sponses were limited and inconsistent compared to
peptide-specific IgG responses in Ivag and IR infected
macaques and there were no detectable Nef or Tat-
specific IgA responses (Figs. 4d and 5d). SIV infection
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Note: “-” denotes no positive responses detected for that specific time point
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via different mucosal routes appears to induce similar
systemic antigen-specific immunoglobulin responses im-
plying vaccine targets should be similar, regardless of the
route of mucosal transmission.
Overall, the majority of the three immunoglobulin
classes bound the same regions of Env peptides (e.g.,
first 31-aa in PP16, Fig. 4a). High Ab binding was
also observed for Env-PP13, V1-V3 regions of gp120,
and gp41. During SIV infection, the majority of the
Env-specific IgG and IgA responses were generated
against gp41, however, this was not statistically sig-
nificant for either route of inoculation when com-
pared to the binding with gp120 (Fig. 4b, p > 0.05).
V2-V3 of gp120 played an important role in inducing
antigen-specific IgM responses.
Gag-specific (p15 and p27) immunoglobulin re-
sponses were limited, and most Ab responses occurred
in the p2, p1 and highly conserved p8 and p6 regions
Fig. 2 Anti-SIV immunoglobulin responses in plasma during SIVMAC251 infection. Whole viral lysate (WVL)-specific immunoglobulin concentrations
was calculated for each antibody isotypes at different time points of SIVMAC251 infection in both intravaginally (n = 6) and intrarectally (n = 7)
inoculated animals. The geometric mean values of the respective responses were shown by the line for the specific time point in each plot.
Asterisks indicate statistically significant differences (p < 0.05) when compared to 13dpi
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Fig. 3 (See legend on next page.)
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(Fig. 5a). PP11 had important B-cell epitopes that
bound to IgG, IgA and IgM Abs (Fig. 5a). The Gag-
specific IgM responses were similar to that of IgG
and IgA, where a moderately strong affinity for the
Gag-PP7 region was detected during acute infection,
however this response diminished in chronic infection
(Figs. 5c & d).
In the IR inoculated SIV-infected RMs, Nef-specific
IgG responses were limited to BG21 and appeared late
during infection (95dpi). However, Nef-specific IgG
Fig. 4 Antigen-specific immunoglobulin responses to linear SIVMAC239 Envelope peptides. a Amino acid sequence of SIVMAC239 Envelope protein,
indicating regions containing potential linear epitopes responsible for peptide-specific IgG, IgA, and IgM responses were shown. Bracketed regions identify
the amino acid sequences used to construct 15mer 10 peptide pools (PP 1–22). Colors refer to the percentage of animals exhibiting peptide-specific
immunoglobulins for that region during infection with SIVMAC251 as shown in the key. Shaded regions show the variable regions V1-5, and the arrow
indicates the proteolytic cleavage site for surface protein gp120 and transmembrane protein gp41. The percentage of macaques with peptide-specific IgG
(b), IgM (c) and IgA (d) responses for SIV-Env peptides are shown for SIV infected macaques inoculated either intravaginally (n= 6) or intrarectally (n= 7).
Responses to individual peptide pools (PP) are shown for each time point (days post infection; dpi). Colors refer to the percentage of animals exhibiting
peptide-specific immunoglobulin responses for that region during infection with SIVMAC251 as shown in the key
(See figure on previous page.)
Fig. 3 a Plasma viral load and number of antigens responsible for IgG responses were plotted for each macaque over the course of 257 days for
intravaginally and 272 days for intrarectally SIVMAC251 infected macaques. Each bar represents breadth (the number of antigens (Env, Gag, Tat
and/or Nef) positive in any combination for IgG responses) at that specific time point. Absence of any bar represents no antigen-specific IgG
responses detected for that time point. b Pearson coefficient of determination analysis between plasma viral load and breadth of IgG responses
were shown for all macaques following SIVMAC251 inoculation for all time points. Note, GN91 had significant correlation values that were shown
in bold numbers. Animal AE14 had no detectable IgG responses upto 236dpi against any SIV antigen and therefore no value of correlation was
determined. R and P denote Pearson R and probability values respectively for each animal when correlated with plasma viral load. P value <0.05
was considered significant
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responses were detected early at 55dpi only in GN91, a
RM from Ivag inoculated SIV-infected group. Moreover,
Ivag inoculated SIV-infected RMs that survived upto
257dpi exhibited Nef-specific IgG responses at late chronic
phase of infection (Fig. 5f). SIV-Nef epitopes varied be-
tween IgG and IgM and were scattered throughout the
Nef protein (Fig. 5e).
Tat-specific responses appeared as early as 73dpi in
Ivag infected macaques compared to IR infected ma-
caques where the responses were detected at 236dpi.
GN91 was one of the several animals with strong re-
sponses to this antigen; however, it showed no differ-
ences in the early generation of these responses when
compared to other animals.
Functional linear Envelope B-cell epitopes are 12 amino
acid in length
SIV-Envelope epitope mapping was performed with
plasma collected from 4 chronically Ivag SIV-infected
macaques (BC35, CL86, CL87 and GN91, more than
150dpi) using the antigen-specific IgG ELISA protocol
as described above. Five to 12-aa peptides from a 15mer
SIV-Env peptide (sequence: KTVLPVTIMSGLVFH in
V3 region) were synthesized commercially (GenScript,
USA) and used as coating antigen at the concentration
of 5 μg/ml to determine the exact length of a linear B-
cell epitope. ELISA cutoff values were determined from
SIV naïve macaques as described above. Positive IgG re-
sponses were detected when peptides with 12aa or
Fig. 5 Antigen-specific immunoglobulin responses to linear SIVMAC239 Gag, Nef and Tat peptides. Amino acid sequences of SIVMAC239 Gag (a) and
Nef (e) proteins, indicating regions containing potential linear epitopes responsible for peptide-specific IgG, IgM and/or IgA responses were shown.
Bracketed regions identify the amino acid sequences used to construct 15mer 10 peptide pools (PP1-13 for Gag and PP1-7 for Nef proteins). Colors
refer to the percentage of animals exhibiting peptide-specific immunoglobulins for that region during infection with SIVMAC251 as shown in the key.
The Gag amino acid sequence (a) was divided into 6 proteins (p15, p27, p2, p8, p1 and p6) with two important regions, p8 (nucleocapsid region) and
p6, shown in shaded area. The percentage of macaques with SIV-Gag peptide-specific IgG (b), IgM (c) and IgA (d) responses, SIV-Nef peptide-specific
IgG (f) and IgM (g) and SIV-Tat peptide-specific IgG (h) and IgM (i) responses were shown for SIV infected macaques inoculated either intravaginally
(n = 6) or intrarectally (n = 7). Responses to individual peptide pools (PP) were shown for each time point (days post infection; dpi). Colors
refer to the percentage of animals exhibiting peptide-specific immunoglobulin responses for that region during infection with SIVMAC251
as shown in the key. Note that Nef- and Tat-specific IgA responses were not detected
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greater in length were tested, which suggests that the
minimum size of the functional linear epitope for elicit-
ing antibodies was 12aa in length (Table 3). Individual
15-mer SIV-Env antigen was also used to determine the
length of B-cell epitope responsible for binding re-
sponses (Fig. 4a).
Discussion
Identification of broadly neutralizing antibodies (bNAbs)
directed at the Env protein provides a possible solution
to generate antibody based vaccine strategies. However,
all HIV vaccines assessed to date were unable to gener-
ate bNAbs. The contribution of bNAbs to the control of
Table 3 Determination of SIV-specific B-cell epitope length by ELISA
aaa denotes amino acid
bPeptides created based upon sequence of SIVMAC239 Envelope peptide (KTVLPVTIMSGLVFH)
c“+” denotes positive response determined by OD/490 ≥ 0.520 for n = 4
Note: Grey shaded area represents the functional linear B-cell epitope (12aa in length) that are binding to plasma IgG in SIV infected animals
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early HIV-1 infection remains uncertain, as bNAbs de-
velop relatively late in infection. Approximately 10–25%
of HIV-1 infected people develop bNAbs within 3-years
post infection [33]. Moreover, SIVMAC251 and SIVMAC239
were shown to be relatively resistant to antibody-mediated
neutralization by both autologous and MAbs treatment
[34, 35]. In our earlier study with either SHIV immunized
or naïve SIVMAC251 challenged macaques, none of the
macaques were able to generate significant levels of neu-
tralizing Abs against either pathogenic SIVMAC251 or
laboratory-adapted SIVMAC251 [23]. In this study, the
presence of NAbs did not predict the outcome of the dis-
ease and moreover the occurrence of those antibodies
might be too late to control the infection at that point.
GN91 was able to control pVL to approximately 1 x 103
RNA copies/ml of plasma and had significantly upregu-
lated WVL-specific IgG and IgM responses compared to
CL87 suggesting that binding Ab responses might be play-
ing an important role in clearing pVL. Our overall data
implies that combination of different peptide-specific IgG
responses are predictive of the control of plasma viremia
compared to the peptide-specific IgM and IgA responses.
Our findings corroborate prior studies showing that while
gp41 and gp120 show high levels of binding to IgG, there
appears to be no correlation with control of early viral
load, and subsequent Env-specific IgG responses had little
impact on disease progression [36–38] when present with-
out additional responses. Gag has been shown to have
little antiviral function [39], however, it appears to be a
strong target for antigen-specific immunoglobulin re-
sponses. The majority of immunoglobulins bind around
the conserved NC, p8, and p6 regions of the Gag protein,
which have several important functions in viral pathogen-
esis, such as viral replication, encapsulating the viral
genome, aiding in reverse transcription, viral genome
packaging, and viral budding [40]. While Gag is not a
target for bNAbs, B-cell recognition of these highly im-
portant and conserved regions of the Gag protein may be
indicative of a potential target for vaccine design. Limited
data are available on the role of Nef-specific Abs in HIV
disease progression. Absence of anti-Nef Abs was found
to be associated with symptomatic HIV infection [41]. In
our study, we identified increased and early Nef-specific
IgG responses in GN91, which controlled pVL much earl-
ier than other disease progressing RMs. Our findings,
along with the recent single domain antibody study for
the inhibition of Nef protein in a mouse model [42], indi-
cate that Nef needs to be considered as an important
target for a novel therapeutic approach in the prevention
and control of HIV. Several studies demonstrated that
Tat-specific antibodies are more common in individuals
who are successfully controlling the disease, suggesting
that Tat-specific Abs have a beneficial role in preventing
disease progression [43–48]. In this study, we detected the
presence of Tat-specific IgG in several animals, but as we
have shown, it appears to be part of a large overall
antigen-specific response that plays role in controlling
pVL. Early induction of IgG responses against important
targets and maintenance of those responses at higher
magnitude might be crucial in reducing plasma viral loads
and a possible predictor of disease outcome.
We also asked whether linear epitopes for antigen-
specific immunoglobulins identified in this study corre-
sponded to bNAb targets. The b12 bNAb recognizes
almost exactly the same region as CD4, where these con-
served regions of the CD4bs [49] fall within Env-PP10 and
PP11 and induced very limited peptide-specific IgM re-
sponses (Fig. 4). However, the CD4bs is highly conform-
ational, whereas only linear epitopes were examined in this
study. Similarly, three series of bNAbs, specifically PG9,
PG16 [50], and CH01-CH04 [51] target conserved con-
formational regions within the variable loops (V1-V3) of
gp120. While these interactions have been shown to be
highly conformational, the analogous V1-V3 regions in SIV-
MAC239 were shown to be strong targets for peptide-
specific IgG, IgA and IgM responses in SIV infected
macaques (Fig. 4). Two bNAbs, 2F5 and 4E10, target the
highly conserved MPER region of gp41 [52]. Linear epi-
topes for 4E10 and 2F5 on HIV-1 strain HXB2 represent
NWFNIT and ELDKWA peptide sequences respectively
[52], and these regions correspond to PP17 region in SIV-
MAC239 (665–678aa). Seventy percent of SIV-infected
macaques generated antigen-specific IgG responses to this
region, and several macaques also generated antigen-
specific IgA responses to this region. Therefore, Env-
specific immunoglobulins bind to several linear epitopes of
recently identified bNAbs, with the exception of the CD4bs.
In future studies, it will be important to define the plasma
viral sequence data in SIV infected animals and determine
if the presence of escape variant(s) have any correlation
with the antigen-specific immunoglobulin responses.
In summary, quantitative and qualitative immuno-
globulin responses were detected in SIV-infected ma-
caques, where increased IgG responses were measured
specifically against the gp41 region followed by variable
regions V1-V3 of gp120, and NC and p6 region of Gag
protein. Antigen-specific IgM and IgA responses were
more limited but targeted towards similar regions of the
Env and Gag proteins. Several regions in Env protein
strongly bind to immunoglobulins and are important
epitopes for bNAbs. Early induction and increased
breadth of antigen-specific IgG responses might be cru-
cial to the control of plasma viral load and predictive of
disease progression in SIV/HIV infection.
Conclusions
Our data strongly suggest that an early induction and in-
creased breadth of peptide-specific IgG responses are
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indicative of disease progression. While Gag-specific re-
sponses may be argued to be an indirect indicator of HIV
disease progression, recent identification of Abs against
Nef and Tat proteins suggests that it may be possible to
prevent and control HIV/AIDS by targeting the function
of Tat and Nef proteins. Moreover, the presence of NAbs
did not predict the outcome of the disease in our study
where the generation of those antibodies might be too late
to control the SIV infection. The experimental design does
not address the role of T-cell responses and other innate
immune responses in regulating plasma viral load in these
SIV-infected animals.
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